In-depth review of the new EMA-approved preventative migraine injection

The European Commission approved Aimovig (erenumab) on July 30th 2018. This comes after approval of Aimovig (erenumab) by the U.S. FDA in May, Australia's TGA on 3rd July, and Swissmedic two weeks ago.

So what is Aimovig (erenumab) and why is this new class of substance so interesting?

The European Commission / EMA approval marks a significant advance in the field of neurology — and one that migraine patients will no doubt welcome. Aimovig (erenumab) is an injection that works by blocking specific molecules, known as calcitonin gene-related peptide (CGRP). Research shows increased levels of CGRP in the body during migraine attacks. Researchers believe that CGRP plays a role in migraine attacks.

The clinical studies of Aimovig (erenumab) reflected a decrease in the overall number of migraine days per month in chronic and episodic migraine patients, which supports the hypothesis that CGRP plays a significant role in this disorder. The EC specifically approved the medicine for “prophylaxis of migraine in adults who have at least 4 migraine days per month”. So for chronic migraine diagnosed individuals, this medicine may offer new hope. 

What does the approval really mean for European migraineurs?

After the EMA approval, each state needs to proceed with making the arrangements for local supply. The approval does not necessarily mean national availability for all migraine patients. Some countries in the EU may never have the medicine available. Pricing may also differ, as it is determined at a national level and usually set/decided upon by the manufacturer. 

Patients looking to access Aimovig (erenumab) today, can do so through everyone.org. Our team of qualified pharmacists and experts source medicines at the lowest possible prices and will guide you through every step of the ordering and importing process for your country. We can have your medicines delivered to you within a week from order.

If you’re a migraine patient, start by discussing this new treatment with your doctor. If you both agree it is suitable for you and you would like to move forward with accessing Aimovig (erenumab) immediately, you can contact us for more information.

You’ll need a prescription from your doctor to order Aimovig (erenumab). Our team will then be able to help you sort out everything needed to ship the medicine to you as quickly as possible. The documentation required varies from country to country, and our team handles each delivery on a case-by-case basis ensuring strict compliance along the way.

A bright future for migraine treatments

"For treatments, I've used Triptans and they worked for a while. One preventive drug that I took for several years with some good results, but had to stop six months ago, was flumarizine (Sibelium). I stopped due to the increased risk of Parkinson's Disease with long-term use. I also used the Cefaly device for four months and it worked well for two months. The new preventive injection medication (Aimovig - erenumab) was interesting to me, but it was frustrating that I couldn't get hold of it. So, my neurologist put me in touch with an American colleague and I'm going over there in August. Meanwhile, a friend put me in touch with everyone.org and I have acquired it with a prescription from my current European neurologist." - Michel, France (diagnosed chronic migraine) read the full story here.

Many migraine patients will understand Michel's frustration in trying a wide range of treatments, without perhaps getting the relief desired. However, the good news is that many pharmaceutical companies are now looking closely at treatments for migraine. The latest approval of Aimovig (erenumab) will hopefully signal a positive step forward in treating migraine, and provide relief to patients who are affected by this debilitating and often under-recognised condition. We at everyone.org will be on the case and as soon as other new medicines are approved we will make them available to everyone, everywhere!